Core Viewpoint - Wanbangde's self-developed innovative small molecule cyclic peptide drug (MCR cyclic peptide) shows superior weight loss effects compared to the existing star drug GLP-1 peptide in preclinical studies on DB/DB obese mouse models [1] Group 1: Drug Efficacy - In an 8-week treatment study, the high-dose group of MCR cyclic peptide resulted in a weight loss approximately 1.25 times greater than that of the GLP-1 peptide group when compared to the control group of DB/DB mice [1] - The treatment significantly slowed down the weight gain trend of DB/DB mice, bringing it closer to the levels of healthy control groups [1] Group 2: Metabolic Benefits - MCR cyclic peptide not only aids in weight loss but also helps in maintaining muscle mass and regulating metabolic indicators such as blood sugar and blood lipids [1] - The comprehensive metabolic regulation suggests the potential for differentiated clinical options in obesity treatment [1]